PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Earnings for PROCEPT BioRobotics Corporation (PRCT)
Earnings in 2023 (TTM): $-105,897,000
According to PROCEPT BioRobotics Corporation's latest financial reports the company's current earnings (TTM) are $-105,897,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of PROCEPT BioRobotics Corporation
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-105,897,000 | $-105,897,000 |
| 2022 | $-87,154,000 | $-93,584,000 |
| 2021 | $-59,853,000 | $-62,384,000 |
| 2020 | $-53,019,000 | $-58,255,000 |
| 2019 | $-41,975,000 | $-42,653,000 |